ALX ONCOLOGY HOLDINGS INC Interest Income (Expense), Nonoperating, Net
ALX ONCOLOGY HOLDINGS INC (ALXO) reported Interest Income (Expense), Nonoperating, Net of $4.28 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-09.
Discontinued › Income Statement › Other Income
us-gaap:InterestIncomeExpenseNonoperatingNet · last filed 2023-03-09
- ALX ONCOLOGY HOLDINGS INC interest income (expense), nonoperating, net for the quarter ending 2022-12-31 was $1.81M, a 8504.76% increase year-over-year.
- ALX ONCOLOGY HOLDINGS INC interest income (expense), nonoperating, net for the quarter ending 2022-09-30 was $1.37M, a 6127.27% increase year-over-year.
- ALX ONCOLOGY HOLDINGS INC interest income (expense), nonoperating, net for the quarter ending 2022-06-30 was $876.00K, a 3708.70% increase year-over-year.
- ALX ONCOLOGY HOLDINGS INC interest income (expense), nonoperating, net for the quarter ending 2022-03-31 was $225.00K, a 800.00% increase year-over-year.
- ALX ONCOLOGY HOLDINGS INC interest income (expense), nonoperating, net for fiscal 2022 was $4.28M, a 4601.10% increase from fiscal 2021.
- ALX ONCOLOGY HOLDINGS INC interest income (expense), nonoperating, net for fiscal 2021 was $91.00K, a 26.61% decline from fiscal 2020.
- ALX ONCOLOGY HOLDINGS INC interest income (expense), nonoperating, net for fiscal 2020 was $124.00K.
- ALX ONCOLOGY HOLDINGS INC interest income (expense), nonoperating, net for fiscal 2019 was -$21.00K.
| Period end | Interest Income (Expense), Nonoperating, Net 3 month | Interest Income (Expense), Nonoperating, Net 3 month as first filed | Interest Income (Expense), Nonoperating, Net 6 month | Interest Income (Expense), Nonoperating, Net 6 month as first filed | Interest Income (Expense), Nonoperating, Net 9 month | Interest Income (Expense), Nonoperating, Net 9 month as first filed | Interest Income (Expense), Nonoperating, Net 12 month | Interest Income (Expense), Nonoperating, Net 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2022-12-31 | $1.81M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $3.18M derived: sum of 2 quarters · filed 2023-03-09 | $4.05M derived: sum of 3 quarters · filed 2023-03-09 | $4.28M 10-K · filed 2023-03-09 | ||||
| 2022-09-30 | $1.37M 10-Q · filed 2022-11-08 | $2.25M derived: sum of 2 quarters · filed 2022-11-08 | $2.47M 10-Q · filed 2022-11-08 | $2.49M derived: sum of 4 quarters · filed 2023-03-09 | ||||
| 2022-06-30 | $876.00K 10-Q · filed 2022-08-08 | $1.10M 10-Q · filed 2022-08-08 | $1.12M derived: sum of 3 quarters · filed 2023-03-09 | $1.14M derived: sum of 4 quarters · filed 2023-03-09 | ||||
| 2022-03-31 | $225.00K 10-Q · filed 2022-05-09 | $246.00K derived: sum of 2 quarters · filed 2023-03-09 | $268.00K derived: sum of 3 quarters · filed 2023-03-09 | $291.00K derived: sum of 4 quarters · filed 2023-03-09 | ||||
| 2021-12-31 | $21.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $43.00K derived: sum of 2 quarters · filed 2023-03-09 | $66.00K derived: sum of 3 quarters · filed 2023-03-09 | $91.00K 10-K · filed 2023-03-09 | -$13.00K 10-K · filed 2022-02-28 | |||
| 2021-09-30 | $22.00K 10-Q · filed 2022-11-08 | -$4.00K 10-Q · filed 2021-11-12 | $45.00K derived: sum of 2 quarters · filed 2022-11-08 | $70.00K 10-Q · filed 2022-11-08 | -$10.00K 10-Q · filed 2021-11-12 | $854.00K derived: sum of 4 quarters · filed 2023-03-09 | ||
| 2021-06-30 | $23.00K 10-Q · filed 2022-08-08 | -$3.00K 10-Q · filed 2021-08-12 | $48.00K 10-Q · filed 2022-08-08 | -$6.00K 10-Q · filed 2021-08-12 | $832.00K derived: sum of 3 quarters · filed 2023-03-09 | $606.00K derived: sum of 4 quarters · filed 2023-03-09 | ||
| 2021-03-31 | $25.00K 10-Q · filed 2022-05-09 | -$3.00K 10-Q · filed 2021-05-17 | $809.00K derived: sum of 2 quarters · filed 2023-03-09 | $583.00K derived: sum of 3 quarters · filed 2023-03-09 | $364.00K derived: sum of 4 quarters · filed 2023-03-09 | |||
| 2020-12-31 | $784.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $558.00K derived: sum of 2 quarters · filed 2023-03-09 | $339.00K derived: sum of 3 quarters · filed 2023-03-09 | $124.00K 10-K · filed 2023-03-09 | -$811.00K 10-K · filed 2021-03-18 | |||
| 2020-09-30 | -$226.00K 10-Q · filed 2021-11-12 | -$445.00K derived: sum of 2 quarters · filed 2021-11-12 | -$660.00K 10-Q · filed 2021-11-12 | |||||
| 2020-06-30 | -$219.00K 10-Q · filed 2021-08-12 | -$434.00K 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | -$215.00K 10-Q · filed 2021-05-17 | |||||||
| 2019-12-31 | -$21.00K 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |